Apitope develops potential first-in-class antigen-specific immunotherapeutics targeting the immunological basis of autoimmune diseases.
We use our novel, proprietary discovery platform to select and develop highly specific peptide-based therapies, known as “apitopes®”, which restore the natural balance (immune tolerance) of the immune system. This mechanism of action avoids global immune suppression and has the broad potential to treat a wide variety of autoimmune diseases.
Apitope’ lead product candidates currently in Phase II clinical development are ATX-MS-1467 for the treatment of Multiple sclerosis (“MS”) and ATX-GD-59 for the treatment of Graves' disease hyperthyroidism.
ATX-MS-1467 is the first potential therapeutic for MS that combines high efficacy with an excellent, and thereby differentiating, safety profile.
ATX-GD-59 demonstrates potential to be the first disease-modifying treatment for Graves' disease and the first potential innovative treatment for the disease in more than 60 years.
In addition, Apitope has developed a robust pipeline with several innovative, potential first-in-class product candidates advancing towards clinical development for the treatment of, amongst other indications, uveitis, factor VIII inhibitors, myocarditis, and rheumatoid arthritis.
Founded in 2002 by Professor David Wraith, as a spin-out from the University of Bristol, Apitope has an experienced leadership team with a strong track record in the pharmaceutical industry and scientific community.
Autoimmune diseases occur when the immune system mounts an undesired response to an innocuous self-antigen, attacking healthy tissues in the body.
Autoimmune diseases are chronic, incurable conditions. They are typically treated with therapies that globally suppress the immune system. Such therapies address the symptoms of the disease, not the immunological basis, and increase the risk of life-threatening infections, cancers and other immune complications.
There are over 80 types of autoimmune diseases including MS, Graves' disease, and uveitis.1
Up to 50 million people are suffering from autoimmune disease in the US alone2, where it is one of the leading causes of death in women in all age groups up to 65.3
The market for autoimmune drugs is large and growing, with five out of the ten best selling drugs in 2016 target autoimmune diseases.4
Potential first in class antigen specific immunotherapies
Apitope uses its novel, proprietary discovery platform to select and develop highly specific peptide-based therapeutics, known as "apitopes®" (antigen processing independent epitopes).
- Are soluble, synthetic peptides based on human protein sequences.
- Are designed to mimic naturally processed epitopes to restore the immune system's natural balance (i.e. tolerance to a self-antigen).
- Selectively target only the immune cells that react to a specific antigen; modulating only the malfunctioning part of the immune system in order to avoid global immune suppression.
- Treat autoimmune diseases at the earliest possible moment in the inflammatory immune response to prevent further tissue damage to the body.
- Have the broad potential to treat a wide variety of autoimmune diseases.
Apitope has a robust pipeline of innovative, potential first-in-class product candidates in clinical and pre-clinical development – View Here
1 Office of Women’s Health US
2 American Autoimmune Related Diseases Association
3 American Journal of Public Health. 90 (9): 1463–6 4. N Engl J Med. Sep 2002 347(12):911–920
4 Speights, K. (2017). The 9 Best Selling Prescription Drugs in 2016